NF-κB and its activator, IκB kinase 2 (IKK2, IKKβ), are central inflammatory molecules in various cell types, including anucleate platelets.
Neither platelet-specific deletion of IKK2 by excision of exon 3 nor pharmacological inhibition of IKK2 affects platelet function.
Platelets are small anucleate cells that release a plethora of molecules to ensure functional hemostasis. It has been reported that IκB kinase 2 (IKK2), the central enzyme of the inflammatory NF-κB pathway, is involved in platelet activation, because megakaryocyte/platelet-specific deletion of exons 6 and 7 of IKK2 resulted in platelet degranulation defects and prolonged bleeding. We aimed to investigate the role of IKK2 in platelet physiology in more detail, using a platelet-specific IKK2 knockout via excision of exon 3, which makes up the active site of the enzyme. We verified the deletion on genomic and transcriptional levels in megakaryocytes and were not able to detect any residual IKK2 protein; however, platelets from these mice did not show any functional impairment in vivo or in vitro. Bleeding time and thrombus formation were not affected in platelet-specific IKK2-knockout mice. Moreover, platelet aggregation, glycoprotein GPIIb/IIIa activation, and degranulation were unaltered. These observations were confirmed by pharmacological inhibition of IKK2 with TPCA-1 and BMS-345541, which did not affect activation of murine or human platelets over a wide concentration range. Altogether, our results imply that IKK2 is not essential for platelet function.
Platelets are key players in hemostasis, and granule secretion is essential for their function. Although platelets lack a nucleus, it has been postulated that the pathway that leads to activation of the inflammatory transcription factor NF-κB is important for their activation and degranulation.1 In general, NF-κB is kept inactive by binding to inhibitory molecules (IκBs). A plethora of stimuli leads to phosphorylation of IκBs by IκB kinases (IKKs), triggering their proteasomal degradation and the release of NF-κB. Most of these activating pathways converge at IKK2, which is the main IκB-phosphorylating enzyme in the course of NF-κB activation.2,3 In platelets, adenosine 5′-diphosphate (ADP), thrombin, epinephrine, and collagen have been reported to cause activation of the IKK2/IκB/NF-κB axis.3 However, although some investigators claim an activating role for this pathway,1,4 others suggest that it has inhibitory effects,5 leaving its role in platelet activation incompletely understood.
We aimed to resolve these conflicting findings for the nongenomic link between the NF-κB pathway and platelet signaling by using a mouse model with a platelet-specific deletion of IKK2,6 combined with in-depth analysis of hemostatic and immunomodulatory platelet functions in vitro and in vivo.
Detailed information is provided in supplemental Methods.
Mice and human samples
Mice with a loxP-flanked exon 3 of the IKK2 gene6 were crossed with PF4-iCre+/− mice7 (IKK2fl/fl PF4-iCre+/−; referred to as IKK2ΔPlt) (both from The Jackson Laboratory on a C57BL/6 background). IKK2fl/fl PF4-iCre−/− littermates were referred to as wild-type (WT). All animal experiments were conducted according to institutional guidelines. The Animal Care and Use Committee of the Medical University of Vienna, as well as the Austrian Federal Ministry of Education, Science and Research, approved all animal experiments (authorization number BMWFW-66.009/0246-WF/V/3b/2016). Human blood samples were taken from healthy volunteers with informed consent based on an approval by the ethics commission of the Medical University of Vienna (allowance number 1738/2015).
If not stated otherwise, data are depicted as mean ± standard deviation. Calculations were performed using GraphPad Prism 6.01 software. Comparison of 2 groups was done using an unpaired Student t test or Mann-Whitney U test if data were not distributed normally. Two or more groups were compared with the respective control group using 1-way analysis of variance with Dunnett correction. Two groups with ≥1 condition were compared by 2-way analysis of variance with Sidak correction.
Results and discussion
We used an IKK2-knockout mouse model in which the region that contains exon 3, coding for the catalytic adenosine triphosphate (ATP) binding site, is flanked by loxP sites (Figure 1A). We crossed these mice with the megakaryocyte/platelet-specific PF4 iCre strain (Figure 1B). Expression of Cre-recombinase results in excision of exon 3 and, thereby, a premature stop codon in exon 4.6 Knockout of IKK2 in megakaryocytes and platelets was confirmed on multiple levels. First, we observed the expected recombination-mediated shift of a genomic sequence in IKK2ΔPlt megakaryocytes (Figure 1C). Consistently, only remnant levels of recombined intron DNA between exon 2 and 3, and megakaryocytic IKK2 messenger RNA, were present (Figure 1D-E). Furthermore, we were not able to detect IKK2 protein in IKK2ΔPlt platelets (Figure 1F).
Next, we investigated potential effects of IKK2 deletion on platelet function. Degranulation was evaluated by surface expression of P-selectin and release of ATP after stimulation of the major platelet activation pathways with proteinase-activated receptor-4 agonist peptide (PAR4-AP), convulxin (CVX) or ADP. Platelet-specific deletion of IKK2 did not affect P-selectin surface expression, CXCL4 release (α-granules) (Figure 1G; supplemental Figure 1A,C), or ATP release (dense granules) (supplemental Figure 1D) at any agonist concentration, pointing toward unaffected degranulation in IKK2ΔPlt platelets. Furthermore, we could not detect any difference in glycoprotein (GP) IIb/IIIa activation, which is needed to sustain tight platelet-platelet interactions upon activation (Figure 1H; supplemental Figure 1B). In vitro aggregation of washed platelets revealed no impairment of IKK2ΔPlt compared with WT platelets (Figure 1I; supplemental Figure 1E-F). In concordance with these in vitro data, we observed no alterations in bleeding time, again indicating unaffected hemostatic functions (Figure 1J). Moreover, we tested platelet aggregation in vivo, as triggered by topical application of FeCl3 onto mesenteric arterioles. In line with the tail-bleeding results, thrombus formation remained unaltered in IKK2ΔPlt mice (Figure 1K). Because platelets exert hemostatic, as well as immunomodulatory, functions, we analyzed platelet-assisted macrophage extravasation upon sterile peritonitis.8 Once more, we could not detect any differences between IKK2ΔPlt mice and littermate controls (Figure 1L). Finally, we examined platelet structure, estimated the amount of young reticulated platelets by measuring RNA content, compared platelet microvesicle release, and evaluated megakaryocyte maturation and differentiation, none of which showed significant differences between WT and IKK2-knockout platelets (supplemental Figure 2).
In principle, some redundancy between IKK2 and related kinases might explain the lack of a clear phenotype after deletion of IKK2. However, the fact that a full knockout results in embryonic lethality9 and multiple observations of functional alterations after conditional deletion of IKK2 in specific cell types6,10-12 argue against such a possibility. In line with that, sequence alignment of IKK2 with the IKK-complex components IKK1 and NEMO and the 2 related kinases IKK-ε and TBK1 shows only moderate similarity (supplemental Figure 3).
Nevertheless, our observations differ from previous findings; deletion of IKK2 in platelets via excision of exons 6/7 on the same genetic background caused severe degranulation impairment and prolonged bleeding.1 It was postulated that absence of functional IKK2 interferes with phosphorylation of SNAP-23 at S95, which was claimed to be essential for fusion of granules with the cell membrane as a prerequisite for full platelet activation. However, in our study, stimulation of platelets resulted in the same degree of SNAP-23 phosphorylation in WT and IKK2ΔPlt platelets (Figure 2A). Similarly, conflicting results were reported for mast cells; an earlier publication claimed IKK2-mediated phosphorylation of SNAP-23,13 whereas a later study postulated that SNAP-23 phosphorylation and mast cell degranulation were, in fact, independent of IKK2.14
A potentially relevant difference between our study and the one that postulated an essential role for IKK2 in platelet activation is the mechanism of IKK2 deletion. Karim et al1 used deletion of exons 6 and 7, which contains the activation loop of IKK210 (Figure 1A), whereas our mouse strain deletes exon 3, coding for the active center of the enzyme.6 Therefore, a putative remnant protein of the exon 6/7 deletion would still possess the ATP binding site of exon 3, which could potentially affect platelet signaling in an unexpected manner. To test this possibility, we generated expression constructs of murine IKK2 mimicking deletion of exon 3 or exons 6 and 7, both with an N-terminal FLAG tag. However, we could only detect FLAG-tagged full-length IKK2 protein but no protein expressed from the deletion constructs (Figure 2B). Additionally, we performed a reporter gene assay to investigate transcriptional activity of NF-κB after expressing the different deletion mimics. Again, only full-length IKK2 was functionally active and induced strong NF-κB activity, whereas both deletion constructs were close to the negative control (Figure 2C). There was a slight difference between the 2 distinct deletion constructs; however, the low NF-κB activity in the range of the negative control would imply that both deletion strategies eliminate IKK2 function. Nevertheless, it cannot be excluded that, in vivo, some residual truncated protein can exert an inhibitory function. Interestingly, deletion of exon 7 alone has been reported to result in a remnant protein that integrates into the IKK complex,11 in line with such a possibility.
In addition to the IKK2-knockout strategy, we tested specific pharmacological inhibition of IKK2 using the compounds BMS-345541 and TPCA-1 at concentrations that inhibit PAR-mediated NF-κB activation in human platelets and basal NF-κB activity in HeLa cells (supplemental Figure 4). Platelets preincubated with BMS-345541 or TPCA-1 were activated with different concentrations of PAR4-AP; however, neither mild nor strong stimulation showed any inhibitory effect of these compounds on platelet degranulation or activation. Interestingly, BMS-345541 even increased platelet activation when high agonist concentrations were used (Figure 2D). Following this, we treated platelets with increasing concentrations of BMS-345541 or TPCA-1 before moderate stimulation with PAR4-AP. However, again we did not observe any effect of IKK2 inhibitors on platelet degranulation or activation (Figure 2E). This was also observed for human platelets treated with IKK2 inhibitors, which did not reduce P-selectin surface expression or GPIIb/IIIa activation after stimulation with 3 different agonists (Figure 2F). These findings differ from those of Karim et al,1 who found an inhibitory effect of these compounds on degranulation of platelets and bleeding times in mice. We have no explanation for this discrepancy. An ineffectiveness of the compounds can be excluded, as we could demonstrate the functionality of our inhibitors by in vitro assays showing that even low basal NF-κB activity in the absence of an activator can be clearly reduced by the compounds at the concentrations that we applied (supplemental Figure 4).
Taken together, we did not observe any effect of exon 3–mediated IKK2 deletion on platelet aggregation, bleeding time, in vivo thrombus formation, dense and α-granule degranulation, or SNAP-23 phosphorylation. Furthermore, pharmacological inhibition of human and murine IKK2 did not result in any degranulation or activation deficiencies. Thus, we provide substantial evidence to question an essential role for IKK2 in platelet degranulation. Nevertheless, this does not rule out that active IKK2, present under inflammatory conditions, has an influence on platelet function.
The authors thank Hannah Paar, Susanne Humpeler, and Bhuma Wysoudil for excellent technical support.
This work was supported by the Austrian Science Fund (project SFB-F54 P07) (J.A.S.).
Contribution: M.S. designed and performed experiments, analyzed data, and wrote the manuscript; S.B., B.M., M.M., B.H., W.C.S., J.B.K.-P., M.H., and K.S. performed experiments; M.I. provided the pS95 SNAP-23 antibody and scientific advice; and A.A. and J.A.S. supervised all research, contributed to the design and interpretation of experiments, analyzed data, and wrote the manuscript.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Johannes A. Schmid, Medical University of Vienna, Institute of Vascular Biology and Thrombosis Research, Schwarzspanierstr 17, 1090 Vienna, Austria; e-mail: firstname.lastname@example.org; and Alice Assinger, Medical University of Vienna, Institute of Vascular Biology and Thrombosis Research, Schwarzspanierstr 17, 1090 Vienna, Austria; e-mail: email@example.com.
The full-text version of this article contains a data supplement.